Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesMetastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era
European Urology, 11/03/09
Lorenzo GD et al. – In past years, there have been considerable advances in the understanding of renal cell carcinoma (RCC) biology. These advances have been translated into the development of several drugs with improved efficacy. Uro–oncologists today have a plethora of treatment options for metastatic RCC patients. Our knowledge will continue to evolve as new data become available, and we hope that knowledge translates to increased efficacy for patients.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09
Article Search
Sponsor